Bosutinib hydrate

EUEMA:by INNUSDailyMed:Bosutinib L01EA04(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 380843-75-4N 5328940 5710 DB06616Y 4486102Y 5018V4‍‍‍‍‍‍​​​‍​​​​​​AEZ0 D03252 CHEBI:39112Y ChEMBL288441Y DTXSID10861568 Interactive image Clc1c(OC)cc(c(Cl)c1)Nc4c(C#N)cnc3cc(OCCCN2CCN(CC2)C)c(OC)cc34 InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)YKey:UBPYILGKFZZVDX-UHFFFAOYSA-NY Bosutinib, sold under the brand nameBosulif, is a small moleculeBCR-ABLandsrctyrosine kinase inhibitorused for the treatment ofchronic myelogenous leukemia. Originally synthesized byWyeth, it is being developed byPfizer.